Sign In
Buy FBLG
$1.07
+0.0200 (+1.90%)
At Close: Jun 03, 2026
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
08:30am, Friday, 16'th May 2025
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the de
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:30pm, Wednesday, 14'th May 2025
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third
FibroBiologics Presents at the ThymUS 2025 Meeting
09:15am, Tuesday, 29'th Apr 2025
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the
FibroBiologics Presenting at the ThymUS 2025 Meeting
09:15am, Tuesday, 29'th Apr 2025
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
08:30am, Friday, 11'th Apr 2025
HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology Located in Houston, Texas, the new facility allow
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
08:30am, Wednesday, 02'nd Apr 2025
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
04:25pm, Monday, 31'st Mar 2025
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing
FibroBiologics Announces 2025 Annual Meeting of Stockholders
08:30am, Thursday, 27'th Mar 2025
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
08:30am, Friday, 21'st Mar 2025
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
08:30am, Tuesday, 04'th Mar 2025
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers Master cell bank to be used in manufacturing of CYWC628 drug product to
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
09:15am, Wednesday, 05'th Feb 2025
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the dev
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
04:30pm, Monday, 30'th Dec 2024
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the dev
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the dev
